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Background: Activating mutations of class III receptor tyrosine kinases (RTK) FLT3, PDGFR and KIT are associated
with multiple human neoplasms including hematologic malignancies, for example: systemic mast cell disorders
(KIT), non-CML myeloproliferative neoplasms (PDGFR) and subsets of acute leukemias (FLT3 and KIT). First generation
tyrosine kinase inhibitors (TKI) are rapidly being integrated into routine cancer care. However, the expanding
spectrum of TK-mutations, bioavailability issues and the emerging problem of primary or secondary TKI-therapy
resistance have lead to the search for novel second generation TKIs to improve target potency and to overcome
resistant clones.
Quizartinib was recently demonstrated to be a selective FLT3 inhibitor with excellent pharmacokinetics and
promising in vivo activity in a phase II study for FLT3 ITD + AML patients. In vitro kinase assays have suggested that
in addition to FLT3, quizartinib also targets related class III RTK isoforms.
Methods: Various FLT3 or KIT leukemia cell lines and native blasts were used to determine the antiproliferative and
proapoptotic efficacy of quizartinib. To better compare differences between the mutant kinase isoforms, we
generated an isogenic BaF3 cell line expressing different FLT3, KIT or BCR/ABL isoforms. Using immunoblotting, we
examined the effects of quizartinib on activation of mutant KIT or FLT3 isoforms.
Results: Kinase inhibition of (mutant) KIT, PDGFR and FLT3 isoforms by quizartinib leads to potent inhibition of
cellular proliferation and induction of apoptosis in in vitro leukemia models as well as in native leukemia blasts
treated ex vivo. However, the sensitivity patterns vary widely depending on the underlying (mutant)-kinase isoform,
with some isoforms being relatively insensitive to this agent (e.g. FLT3 D835V and KIT codon D816 mutations).
Evaluation of sensitivities in an isogenic cellular background confirms a direct association with the underlying
mutant-TK isoform – which is further validated by immunoblotting experiments demonstrating kinase inhibition
consistent with the cellular sensitivity/resistance to quizartinib.
Conclusion: Quizartinib is a potent second-generation class III receptor TK-inhibitor – but specific, mutation
restricted spectrum of activity may require mutation screening prior to therapy.
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Gain-of-function mutations of the FLT3, KIT and
PDGFR class III receptor tyrosine kinases (RTK) play
important roles as oncogenesis-driving events in several
hematologic malignancies. For example, FLT3 mutations
are predominantly found in AML associating with a
poor prognosis [1-4], but are also reported in (pediatric)
acute lymphoblastic leukemia (ALL) [5]. KIT mutations
occur in the vast majority of systemic mastocytosis (SM)
[6] and subsets of acute leukemia, including core-
binding factor (CBF) [7] and pediatric [8] AML. Certain
FLT3 and KIT mutations correlate with inferior outcome
in adult AML [4,9,10].
PDGFR mutations are frequently found in myeloprolif-
erative disorders, such as Philadelphia chromosome-
negative chronic myeloid leukemia (CML), where
PDGFR alpha or beta fuses with another gene allowing
autoactivation of the tyrosine kinase. Several fusion part-
ners have been described, including FIP1L1 leading to
the FIP1L1-PDGFRA fusion gene. This translocation has
been associated with hypereosinophilic syndromes and
mastocytosis with eosinophilia [11-13].
Numerous tyrosine kinase inhibitors have been devel-
oped to target class III RTKs (see also Discussion).
These TKIs have a variable spectrum of activity against
different class III RTKs and against various mutant
isoforms of these kinases. To date, translation from
bench to bedside has resulted in only modest or short-
lived effectiveness of these inhibitors in most entities
[14-23] and only a few agents have achieved FDA-
approval for selected indications such as CML and HES.
With the exception of Ph+ALL, no TKIs have been ap-
proved for treatment of acute leukemia so far.
Quizartinib is a novel second generation class III re-
ceptor tyrosine kinase inhibitor with superior pharma-
ceutical properties and an excellent pharmacokinetic
profile compared to other agents. Quizartinib was dem-
onstrated to have high efficacy and tolerability in tumor
xenograft models that express a FLT3 ITD mutant kin-
ase [24,25].
A previous study used recombinant enzyme in in vitro
kinase assays to identify that quizartinib targets related
class III RTKs, such as wildtype and gain-of-function
mutant KIT and PDGFR isoforms [24].
Using several cell based assays, we now show, that
quizartinib treatment of leukemic cells leads to inhib-
ition of mutant KIT, PDGFR and FLT3 isoforms - with
resultant inhibition of cellular proliferation and induc-
tion of apoptosis. These effects are seen in vitro as well
as ex vivo (primary leukemic blasts). Importantly, potent
antitumor activity was seen against distinct (mutated)
kinase isoforms, including FIP1L1-PDGFRA, and FLT3
ITD, FLT3 TKD1 and FLT3 TKD2 mutations. Whereas
some mutant-KIT and –FLT3 isoforms were sensitive toquizartinib treatment, some mutations such as FLT3
D835V and the most prevalent KIT gain-of-function mu-
tation detected in CBF AML, KIT D816V, was relatively
insensitive with regard to quizartinib treatment.
Quizartinib is currently under clinical investigation in
FLT3 ITD and wildtype AML. Our data suggests that
quizartinib may be an attractive agent for clinical investi-
gation in other settings as outlined here. This would not
include the group of mutant-KIT CBF AML that have
KIT D816V mutations. However, patients with CBF
AML with KIT D816Y or exon 11 mutations or patients
with solid tumors associated with KIT and PDGFR muta-
tions, such as GIST might benefit from this agent. Clin-
ical mutation analysis could help identify individuals
that are the most likely to respond to quizartinib.
Results
Quizartinib inhibits cellular proliferation of mutant-FLT3, -
KIT or –PDGFRA leukemia cell lines in a dose dependent
manner
Quizartinib was previously reported to be a potent in-
hibitor of wildtype FLT3 and FLT3 ITD kinases [24].
Structural considerations suggest quizartinib could in-
hibit other members of the class III RTK family that are
frequently mutated in leukemia or myeloproliferative
disorders (i.e. KIT and PDGFR). These findings
prompted us to evaluate quizartinib sensitivity in a var-
iety of leukemia cell line models harboring RTK
mutations.
The human mast cell leukemia cell lines HMC1.1 (KIT
V560G) and HMC1.2 (KIT V560G + D816V), the murine
mast cell line p815 (harboring a KIT D814Y mutation
analogous to the human D816Y mutation), the eosino-
philic leukemia cell line EOL-1 (FIP1L1-PDGFRA), the
CBF AML cell line Kasumi-1 (N822K), the myeloid
leukemia cell line MOLM14 (heterozygous FLT3 ITD),
M-07e (growth factor dependent wildtype KIT), the APL
cell line HL60 (growth factor independent, wildtype
FLT3 and KIT), the lymphoblastic leukemia cell line
Jurkat (no known activated RTK) and the CML blast cri-
sis cell line K562 (BCR/ABL1) were treated with
quizartinib in a dose-dependent manner for 48 hours
and the cellular antiproliferative capacity was measured
using an XTT-based assay.
The proliferation of cell lines with FLT3 ITD (MV4;11,
MOLM14), FIP1L1-PDGFRA (EOL-1), ligand-stimulated
wild-type KIT (M0-7e), or certain KIT mutations (KIT
exon 11 V560G, HMC1.1; Kasumi KIT exon 17 N822K)
was strongly inhibited by quizartinib (Figure 1). In con-
trast, the proliferation of a cell line with a KIT exon 11
V560G and KIT exon 17 D816V mutation on the same
allele (HMC1.2) was basically insensitive to quizartinib.
Noteworthy, the murine cell line p815, harboring an al-
ternative (tyrosine) substitution at the same codon (KIT
Figure 1 Quizartinib inhibits cellular proliferation of KIT-, FLT3- or PDGFR-dependent leukemia cells. Dilution series of quizartinib for
several cell lines harboring mutant-FLT3, ABL1 or PDGFRA (1A) or mutant-KIT isoforms (1B) were performed and cellular proliferation was assessed
using an XTT-based assay. Sensitivity towards quizartinib varied widely between the tested cell lines. IC50s and mutation isoforms for all tested
cell lines are listed in Table 1.
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retained intermediate sensitivity to quizartinib.
As experimental controls, we also tested quizartinib
against several cell lines lacking an activated type III
RTK (K562 [BCR-ABL1], Jurkat [no known tyrosine kin-
ase oncogene], and HL60 [no known tyrosine kinase
oncogene, but expressed wild-type FLT3]; quizartinib
had no meaningful anti-proliferative effects against these
cell lines (IC50 > 10,000 nM; Table 1).
DMSO alone, used in the highest concentration in any
of the quizartinib dosing experiments, had no significant
antiproliferative effect (MOLM14 cell line, Table 1).
To further show the specificity of the anti-proliferative
effect of quizartinib, we tested the effects of this drug
against M-07e cultured in GM-CSF rather than SCF:
Whereas the SCF-stimulated M-07e were sensitive to
quizartinib (IC50 77 nM), GM-CSF stimulated M-07e
were completely resistant (quizartinib IC50 > 10,000 nM).
Notably, the sensitivity patterns observed for different
mutant RTK isoforms were not totally consistent with
IC50s previously published in a kinase assay reported by
Zarrinkar and colleagues [24] (e.g. IC50KIT D816V 150
nM versus >1500 nM in our assays). There are several
possible explanations for this disparity. First, the results
by Zarrinkar et al. were performed using drug binding to
recombinant kinases as opposed to enzymatic inhibition
of full-length cellular kinases. Second, while we did not
change FBS levels prior to quizartinib administration
(10% for leukemia cell lines, 20% for native leukemia
blasts) – the earlier report by Zarrinkar et al.
[24] used cells that were pre-sensitized by exposure
to reduced serum levels (0.5% FBS) 12 hours prior to
therapy.
Serum deprivation is a commonly used method to
reduce serum-drug interactions – but also has profound
cellular effects including accumulation and synchronization
of cells in the G1/G0 [26]. Moreover, given the high
protein binding of quizartinib (99% protein bound), it isnot surprising that changes in serum concentration
would affect drug potency in cell-based models.
For example, we repeated our experiments with the
KIT D816V-positive cell line HMC1.2, but this time cul-
tured the cells in serum-reduced media overnight prior
to quizartinib treatment the next day. This change in
experimental conditions profoundly altered the anti-
proliferative effect of quizartinib, as the IC50 for serum-
deprived cells was ~260 nM compared to the serum
replete conditions (IC50 ~1700 nM). The potency of the
serum-deprived cells is in the range of the predicted
IC50 for the D816V mutation reported by Zarrinkar
et al. [24] (Table 1).
This effect was further validated using an isogenic
cell model as well as native FLT3 ITD positive
leukemia blasts as described below. (Please, refer to
Table 2 and Additional file 1: Figure S1 for similar ex-
periments using native cells and to Table 3 for serum-
deprivation experiments using Ba/B3 FLT3 ITD and
KIT D816V cells).
Quizartinib induces apoptosis in in vitro leukemia cell
lines
The extraordinary antiproliferative effect seen in some
cell models tested, was also accompanied by microscop-
ically condensed pyknotic cells that accumulated over
time. This observation suggests that quizartinib may in-
duce apoptosis via inhibition of (mutant) FLT3, KIT or
PDGFRA.
Using an annexin V-based immunofluorescence
assay, we were able to demonstrate potent dose-
dependent induction of apoptosis in several leukemia
cell lines:
In analogy to the demonstrated antiproliferative ef-
fects, evaluation of quizartinib in several cell lines lack-
ing an activated type III RTK (K562, Jurkat and HL60)
did not reveal any significant proapoptotic effects. In
contrast, cell lines harboring FLT3 ITD (MV4;11,
Table 1 Non-linear regression analysis of IC50s (Antiproliferation)
Cell line Target IC50 (nM)
Inhibition of proliferation
HMC1.1 KIT V560G 14
HMC1.2 KIT V560G/D816V 1727
HMC1.2, 0.5% FBS KIT V560G/D816V 263
p815 KIT D814Y (murine) 445
Kasumi-1 KIT N822K 36
M-07e + SCF KIT-activated 77
M-07e + GM-CSF GM-CSF signaling not reached*
EOL-1 FIP1L1-PDGFRA 1
K562 BCR/ABL not reached*
HL60 unknown not reached*
Jurkat unknown not reached*
MV4;11 FLT3 ITD (hemizygous) < 1
MOLM14 FLT3 ITD < 1
MOLM14 + DMSO FLT3 ITD not reached*
Pat.221 CBF AML (KIT WT) 675
Pat.279 CBF AML (KIT WT) / FLT3 amplification (subclone)? 3434
Pat.299 CBF AML (KIT WT) 7248
Pat.305 CBF AML (KIT WT) 7079
Pat.375 CBF AML (KIT N/A) 503
Pat.379 CBF AML (KIT WT) 806
Pat.368 FLT3 amplification ? 2700
Pat.601 FLT3 ITD 1153
Pat.176 FLT3 ITD (Beta1) not reached*
Pat.602 FLT3 ITD (Beta1) not reached*
* tested up to 10 000 nM.
The table summarizes estimated IC50 values obtained by non-linear regression analysis for the antiproliferative activity of quizartinib in leukemia cell lines and
primary native leukemia blasts.
The cell line HMC1.2 was additionally pre-treated with reduced serum (0.5% FBS) to address the influence of methodology aspects on sensitivity profiles. To
exclude solvent-associated non-specific cytotoxicity, the MOLM-14 cell line was treated with DMSO using the highest concentration for the quizartinib
dose experiments.
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GM-CSF)-stimulated wild-type KIT (M0-7e), or certain
KIT mutations (KIT exon 11 V560G, HMC1.1; Kasumi
KIT exon 17 N822K) potently underwent apoptosis
upon quizartinib exposure with IC50s in the lower
nanomolar ranges (Table 2). Notably, IC50s were similar
or somewhat higher compared to the antiproliferative ef-
fects achieved in these cell lines (compare with Table 1).
HMC1.2, the sister cell line of HMC1.1 harboring an
additional KIT D816V mutation, revealed a complete
loss of sensitivity towards quizartinib in all tested doses
(Figure 2; IC50s are provided with Table 2). This finding
suggests that the distinct mutant-KIT isoform directly
orchestrates sensitivity towards quizartinib. In this con-
text it is noteworthy, that the KIT D814Y-positive
(D816Y in human KIT) murine cell line p815 was stillcapable to induce apoptosis with an IC50 in the hun-
dreds nanomolar range (Figure 2).Comparison of quizartinib sensitivity towards different
leukemia-driving KIT and FLT3 mutations in an isogenic
cellular background
Quizartinib potently inhibits cellular proliferation and
induces apoptosis in leukemia cell lines that are
dependent on FLT3, KIT or PDGFRA activity. However,
the potency of quizartinib differs widely between the
tested cell lines – from complete insensitivity to doses in
the low nanomolar range.
The divergent inhibitory effects may be due to dif-
ferential sensitivity profiles of different (mutant) RTK
isoforms (compare findings about HMC1.1 versus HMC1.2
Table 2 Non-linear regression analysis of IC50s (Apoptosis/Viability)
Cell line Target IC50 (nM)
Induction of apoptosis
HMC1.1 KIT V560G 31
HMC1.2 KIT V560G/D816V not reached*
p815 KIT D814Y (murine) 341
Kasumi-1 KIT N822K 67
M-07e + SCF KIT-activated 78
M-07e + GM-CSF unspecific stimulation not reached*
EOL-1 FIP1L1-PDGFRA < 1
K562 BCR/ABL not reached*
HL60 N/A not reached*
Jurkat N/A not reached*
MV4;11 FLT3 ITD (hemizygous) 2
MOLM14 FLT3 ITD 3
GIST822 KIT K642E 109
GIST48 KIT V560D/D820A not reached*
Pat.368 FLT3 amplification ? 2998
Pat.601 FLT3 ITD 876
Pat.695, 20% FBS FLT3 ITD 2335
Pat.695, 0.5% FBS FLT3 ITD 25
Pat.139, 20% FBS FLT3 ITD, Relaps 760
Pat.139, 0.5% FBS FLT3 ITD, Relaps 10
Reduction of viable cells
Pat.507 CBF AML (KIT WT) 1275
Pat.317 CBF AML (KIT D816Y) 1294
Pat.521 CBF AML (KIT WT) 2018
Pat.305 CBF AML (KIT WT) 2954
Pat.511 CBF AML (KIT WT) 4272
Pat.281 CBF AML (KIT WT) 5758
Pat.279 CBF AML (KIT WT) / FLT3 amplification? (subclone) 6607
Pat.523 CBF AML (KIT WT) 7175
Pat.361 CBF AML (KIT D816V) 8443
Pat.239 CBF AML (KIT D816V) not reached*
* tested up to 10 000 nM.
The table summarizes estimated IC50 values obtained by non-linear regression analysis for the cytotoxic activity of quizartinib in leukemia cell lines and primary
native leukemia blasts. Native patient blasts were cultured in 20% FBS." to "Cell lines were cultured in 10% FBS; native patient blasts were cultured in 20% FBS. To
address methodology aspects towards sensitivity profiles two native FLT3 ITD + patient samples (Pat. 695 with newly diagnosed AML, Pat. 139 with relapsed AML)
were co-treated with reduced serum (0.5% FBS).
In addition IC50 estimates for the proapoptotic effect of quizartinib in the imatinib-sensitive GIST solid tumor cell line GIST882, harboring a K642E mutation, and
the imatinib-insensitive cell line GIST48, harboring a V560D mutation in addition to a D820A mutation in the tyrosine kinase domain, are provided, revealing
sensitivity profiles similar to imatinib.
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omic abnormalities contributing to leukemogenesis and
resistance to therapeutics.
To exclude cell line-specific off-target biology interfer-
ing with the effects of kinase-inhibition, we tested
leukemia-driving RTK mutations in an isogenic cellular
background: Various human (mutant) FLT3 or KIT
isoforms were stably transfected in the IL3-dependentmurine pro B-cell line Ba/F3. Activation of the transfected
mutant isoforms was demonstrated by selecting for cells
with IL-3 growth factor-independent proliferation. How-
ever, BaF3 cells expressing wildtype KIT or FLT3 isoforms
required the addition of the corresponding ligand, (KIT
(SCF) or FLT3 (FLT3L)).
We were able to directly cross-check the clinically
most relevant RTK mutations in acute leukemia (i.e.
Table 3 Estimated IC50s for the proapoptotic and antiproliferative effects of quizartinib in an isogenic cell model of
Ba/F3 cells transfected with various mutant TKs
Isoform Mutation locus IC50 (nM) IC50 (nM) IC50 (nM) IC50 (nM)
Ba/F3 transfectants leukemia cell lines
Inhibition of proliferation Induction of apotosis Inhibition of proliferation Induction of apotosis
BCR/ABL fusion n.r.* n.r.* not reached (K562) n.r.* (K562)
FLT3 WT N/A 49 11
FLT3 ITD, 10% FBS juxtamembrane domain 9 5 <1 (MOLM14) 3 (MOLM14)
FLT3 ITD, 0.5%FBS juxtamembrane domain <1 N/D
FLT3 K663Q tyrosine kinase domain I 14 23
FLT D835V tyrosine kinase domain II 172 888
FLT3 D835Y tyrosine kinase domain II 84 24
KIT WT N/A 474 n.r.* 77 (M0-7e) 210 (MO-7e)
KIT D816F tyrosine kinase domain II 2871 6254
KIT D816V, 10% FBS tyrosine kinase domain II 3074 8982 1727 (HMC1.2) n.r.* (HMC1.2)
KIT D816V, 0.5% FBS tyrosine kinase domain II 633 N/A
KIT D816Y, 0.5% FBS tyrosine kinase domain II 366 611 445 (p815) 341 (p815)
parental N/A n.r.* n.r.*
parental + DMSO N/A n.r.* n.r.*
*(not reached with tested doses up to 10 000 nM).
Sensitivity of quizartinib is distinct to and differs widely in between different tyrosine kinase isoforms transfected into an isogenic Ba/F3 cellular background.
Estimated IC50s were computed using non-linear regression analysis of an average mean of at least 3 experiments for each cell line.
If applicable, IC50s of leukemic cell lines harboring a similar mutation are provided (rows on the right).
Influence of serum-deprivation on sensitivity profiles of quizartinib was tested in two cell strains (Ba/F3 FLT3 ITD or KIT D816V): Cells were cultured in media with a
reduced serum concentration (0.5% FBS) and treated with quizartinib the next day.
Solvent-associated non-specific cytotoxicity was excluded using the parental Ba/F3 cell strain treated with DMSO in the highest concentration used for the
quizartinib dose experiments.
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an isogenic Ba/F3 background against a panel of
leukemic cell lines harboring a corresponding RTK mu-
tation. Comparison of inhibition of cellular proliferation
after quizartinib treatment revealed strong correlation
between naturally occurring and engineered cell lines ex-
pressing identical mutant kinases (Figure 3A): Ba/F3
cells stably transfected with a vector encoding for a
FLT3 ITD were equally highly sensitive to quizartinib
compared to the human FLT3 ITD positive leukemia cell
line MOLM14. Vice versa, transfection of a KIT D816V
mutation retained Ba/F3 cells highly resistant towards
quizartinib, which is consistent with findings in the hu-
man mast cell leukemia cell line HMC1.2 as discussed
earlier. Interestingly, replacing the valine substitution
with tyrosine at codon 816 (D816Y) rendered Ba/F3 cells
to relative sensitivity to quizartinib – so was the KIT
D814Y-positive cell line p815.
This observation is not unique to quizartinib – but is
in line with previous data for other KIT tyrosine kinase
inhibitors, such as dasatinib [27]. In this context, a
recent study suggested structural reasons that underlay
drug sensitivity of different mutant-KIT kinases using
sunitinib and imatinib mesylate [28].Surprisingly, transfection of BCR/ABL1 into Ba/F3
cells not only did not halt proliferation of cells – but did
confer a proliferation advantage for quizartinib treated
cells in a dose-dependent manner. This observation de-
serves further exploration with regard to molecular
mechanisms.
Together, these findings suggest a direct mutant-
specific tyrosine kinase-mediated effect of quizartinib to-
wards modulation of cellular proliferation. Table 3 pro-
vides additional information of sensitivity patterns, with
regard to inhibition of proliferation as well as induction
of apoptosis, for several mutant-FLT3, -KIT and BCR/
ABL1 isoforms transfected into an isogenic Ba/F3 cellu-
lar background: Of note, transfection of a FLT3 D835V
kinase domain mutation, which is homologous to
D816V in KIT, reveals restricted sensitivity towards
quizartinib – which is in line with a recent study by Smith
and colleagues demonstrating a conformational clash
preventing proper binding of quizartinib to the FLT3
binding pocket [29]. Importantly, our data further show
that alternative substitution of aspartic acid with a
tyrosine residue (D835Y) renders cells to sensitivity,
which underlines our findings for KIT D816Y as
discussed above.
Figure 2 Quizartinib potently induces apoptosis in selected leukemia cell line models. Leukemia cell lines harboring FLT3, KIT or PDGFRA
mutations were treated with various doses of quizartinib for 48 hours and induction of apoptosis was measured using an annexin V-based assay.
Representative density plots indicating early phase apoptosis (annexin V-positive cells) or late phase apoptotic cells (propidium iodide positivity)
fractions are shown in a quadrant density dot plot. Whereas the FLT3 ITD + cell line MOLM14 (A) and the mutant-KIT V560G + cell line HMC1.1 (B)
reveal potent sensitivity in the lower nanomolar range, the sister cell line HMC1.2 (C), harboring an additional KIT D816V mutation, is insensitive
towards quizartinib treatment. Data presented in the dose–response curves on the right represents the average mean of at least 3 separate
experiments (each normalized to the untreated controls, which are set to zero). IC50s of all tested cell lines are provided in Table 2.
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inhibition of phosphorylation of the target receptor
tyrosine kinase in an isogenic cell model
In our cell biology experiments, the sensitivity of the tested
cell lines to quizartinib was linked to inhibition of (mutant)
class III RTK. The isogenic cell models confirm IC50s
obtained for the leukemia cell lines harboring similar
mutations, further suggesting a direct interaction of tyro-
sine kinase inhibition and the observed antiproliferative
and proapoptotic effects in the tested cell lines (rather than
off-target effects).
To address this question at the protein level, we add-
itionally performed immunoblotting experiments for Ba/
F3 cell lines transfected with mutant KIT or FLT3
kinases and treated with quizartinib for 90 minutes.
Indeed, sensitivity towards quizartinib, as indicated by
loss of RTK autophosphorylation, proved to be kinase-
specific and was in agreement with the functional assays
using the same cell lines. Notably, the KIT D816Vmutation, exchanging aspartic acid for valine at codon
816 and thus rendering the kinase autophosphorylated,
does not show significant reduction of phosphorylation
levels – while tyrosine or phenylalanine substitutions at
the same codon (D816Y or D816F), similarly leading to
autoactivity of the kinase, proof to be sensitive towards
quizartinib treatment with loss of autophosphorylation
in the nanomolar ranges (Figure 3B). Interestingly,
D816Y was thereby dephosphorylated at the glycosylated
membrane-bound (~145 KDa), as well as the intracellu-
lar isoform (~125 KDa) – whereas sensitivity of D816F
was virtually restricted to the glycosylated isoform.
These results are in line with the viability assays pro-
vided in Figure 3A and Table 3, and again argue against
nonspecific off-target – but for TK-mediated effects.
Moreover, it underlines that TKI sensitivity patterns
are not just tyrosine kinase, kinase-domain or codon
specific – but may even depend on the type of amino
acid substitution at a given codon.
Figure 3 Cellular effects of quizartinib are tyrosine kinase-mediated (A) Quizartinib displays distinct antiproliferative effects of
genetically altered Ba/F3 cells in dependence of the tyrosine kinase isoform transfected. The sensitivity of inhibition of proliferation is
thereby similar to the sensitivity achieved in natural leukemia cell lines harboring a similar mutation. Estimated IC50s are provided in Table 3
along with IC50s for the proapoptotic effects in the same cellular context. (B) The observed cellular effects are directly linked to the potency of
inhibition of phosphorylation of mutant-KIT and FLT3 isoforms. Whole cell lysates of Ba/F3 cells transfected with different human mutant-KIT or -
FLT3 isoforms were immunoblotted using a pan-phosphotyrosine antibody or a total-KIT or -FLT3 antibody. Pretreatment of cells with quizartinib
revealed isoform-specific inhibition of phosphorylation. Notably, inhibition of phosphorylation of the D816V mutation was significantly reduced
compared to the D816Y and D816F isoforms.
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translates into ex vivo antiproliferative effects in native
leukemia blasts
We further evaluated the antiproliferative effects of
quizartinib using native blasts isolated from patients
with newly diagnosed FLT3- or KIT-activated AML (add-
itional patient characteristics are provided in Additional
file 2: Table S1 with the online version of the article).
Notably, quizartinib was able to inhibit proliferation of
ex vivo CBF AML blasts and FLT3 ITD positive blasts in
the upper nanomolar or lower micromolar ranges
(Table 1).
CBF AML is associated with high CD117 (i.e. KIT)
expression and/or autoactivating mutations within the
KIT gene [7]. KIT mutation screening of exons 8, 9, 11,
13 and 17 was performed. No autoactivating mutation in
our patient cohort used for antiproliferation assays was
detected, suggesting a paracrine activation of KIT in the
quizartinib-responsive patient cohort as demonstrated
earlier for ~50% of FLT3/KIT wildtype patients [30].
In FLT3-associated leukemia patients, the anti-
proliferative effect of quizartinib was inconsistent – withrefractory as well as sensitive cases identified. For example,
one case sensitive to quizartinib treatment was from a pa-
tient with an MLLT3-MLL rearrangement (patient #368).
We were not able to detect any FLT3 or KIT mutations in
this patient – although, karyotyping revealed trisomy of
chromosome 13 (FLT3 genomic location), which poten-
tially contributed to treatment response via FLT3 amplifi-
cation. Potent inhibition of amplified FLT3 wildtype gene
via quizartinib was recently shown in an in vitro leukemia
cell model using the SEM-K2 ALL cell line by
Gunawardane and colleagues [31]. Another of our cases
demonstrating sensitivity towards quizartinib harbored a
FLT3 ITD, but interestingly, two more cases with a FLT3
ITD were refractory to quizartinib (patient #176 and #602).
FLT3 ITD sequencing revealed that the internal
tandem duplication was located in the beta1 sheet of the
first tyrosine kinase domain in both resistant cases. This
particular class of mutant kinase is resistant to FLT3
inhibition by midostaurin (PKC412) and is associated
with a poor clinical outcome [32-34]. Our data suggests
a similar sensitivity profile for quizartinib against FLT3
ITD-beta1 mutant kinases.
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cells
We next tested isolated native blasts derived from
patients with newly diagnosed AML to confirm the
proapoptotic effect observed for quizartinib in in vitro
leukemia and isogenic mutant-TK models (IC50s for all
patients are provided with Table 2; patient characteristics
are available as supplementary material in Additional file 2:
Table S1).
One sample, taken from a bone marrow aspirate of a
patient with de novo AML, was identified to harbor a
FLT3 ITD mutation in the juxtamembrane domain of
the gene (patient #601). IC50 was in the higher
nanomolar range – which is considerably higher com-
pared to the in vitro FLT3 ITD models. The cause of this
discrepancy is unknown, but is commonly observed in
ex vivo blasts compared to in vitro models [35,36]. In
addition to the above comments about the effect of
serum concentration on sensitivity to quizartinib, other
genomic abnormalities acquired in the context of com-
plex cytogenetic AML may have contributed to the
observed effects in cultured ex vivo blasts.
In a second patient sample, obtained from the bone
marrow aspirate of an elderly patient with MLL-associ-
ated AML – including trisomy of chromosome 13 (lead-
ing to overrepresentation of the FLT3 gene), quizartinib
treatment induced apoptosis in these cells with an IC50
~3000 nM. Due to the high bioavailability of quizartinib,
ex vivo IC50s in the lower micromolar ranges may trans-
late into antileukemic activity in vivo – but this observa-
tion needs clinical validation.Figure 4 Quizartinib reduces the proportion of viable cells in samples
containing 20% FBS and treated with different concentrations of quizartinib
cell fraction was gated in a FSC/SSC scatter and viability was confirmed usi
for annexin V and PI. (B) Relative reduction of the proportion of viable cells
effect plot of all tested concentrations of quizartinib is shown on the right.
samples are provided in Table 2.A subset of native leukemia samples analyzed pre-
sented with a high proportion of dead/apoptotic cells in
the untreated control samples. This obscured conven-
tional analysis via annexin/PI staining of proapoptotic
effects induced by quizartinib treatment. Nevertheless,
we were able to assess reduction of the proportion of
viable cells in a cohort of CBF AML patients 48 hours
after quizartinib treatment compared to treatment-naive
cells (Figure 4 for representative analysis of one patient).
Table 2 provides a summary of IC50s of all tested
samples.
The cytotoxic effect of quizartinib varied widely. Ana-
lysis of the KIT mutation status revealed a wildtype gene
for KIT in most patients – some of these were sensitive
to quizartinib therapy, arguing for paracrine activation
of KIT or FLT3 [30].
Of interest, similar to our cell line results, two patients
with a KIT D816V mutation revealed relative insensitiv-
ity towards quizartinib. However, as predicted by our
in vitro models (see also Figure 3), one patient with CBF
AML harboring the less common KIT D816Y mutation
demonstrated sensitivity with an IC50 for reduction of
viable cells of approximately 1300 nM. Notably, this lies
in the same range as seen for the proapoptotic effect of
ex vivo blasts of a newly diagnosed treatment-naive
patient (patient #601) harboring a FLT3 ITD (JM)
mutation. Additional patient characteristics are provided
in Additional file 2: Table S1 with the online version of
the article.
In general, the reported IC50s in our study for native
leukemia cells lie in contrast to a previous report byof native leukemia cells. Patient samples were cultured in DMEM
for 48 hours. (A) The plot of one patient is shown. The mononuclear
ng an annexin V/propidium iodide (PI) stain demonstrating negativity
in response to quizartinib was assessed by flow cytometry. A dose-
Estimated IC50s by non-linear regression analysis of all tested patient
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IC50s for FLT3 ITD-positive native blasts in the lower
nanomolar ranges.
Several issues need to be discussed in this context.
Besides individual cell-context specific additional effects
(such as additional mutations rendering signal transduc-
tion pathways or drug sensitivities), which may have
obscured TK-targeted effects of quizartinib, a couple of
methodology-related aspects need to be addressed: As
discussed earlier, we did not use serum reduced condi-
tions in our assays – but serum-rich media containing
10% FBS for cell lines and 20% FBS for experiments
involving native blasts. Moreover, it has been reported
that blasts obtained from patients with relapsed FLT3
ITD-positive leukemia may show higher sensitivities
towards tyrosine kinase inhibitors due to a higher ad-
diction to FLT3 gain-of-function signal transduction of
leukemia blasts in the relapse setting compared to de
novo AML samples [37]. Notably, the Zarrinkar study
evaluated the efficacy towards quizartinib in relapsed
patients while our work included only specimens from
newly diagnosed patients. We addressed these issues
and treated a newly diagnosed patient with AML as
well as a patient with relapsed AML, both harboring a
FLT3 ITD mutation, with quizartinib in a dose-
dependent manner. Both samples were cultured in
serum-repleted (20% FBS) as well as serum-reduced
(0.5% FBS) conditions. In line with our theory, the
average concentration to induce apoptosis was mark-
edly reduced with IC50s in the low nanomolar range
in samples cultured in serum-reduced conditions. Even
more, sensitivity towards quizartinib was increased in
the relapsed leukemia patient. Exemplary AnnexinV-
based density plots illustrating the influence of culture
conditions with regard to the achievable proapoptotic
effects (~22% versus 80% dead/apoptotic cells upon
exposure to 10 nM quizartinib when cultured in 20%,
resp. 0.5% FBS) are provided as Additional file 1:
Figure S1; IC50s are provided with Table 2.
Antitumor activity of quizartinib in mutant-KIT solid
tumor cell lines
Besides acute leukemia, KIT mutations are found in a
large proportion of gastrointestinal stromal tumors
(GIST) [38], in subsets of seminomas [39] and me-
lanoma [40]. PDGFR mutations are further reported in
myeloproliferative disorders and GIST as well [38].
KIT or PDGFRA tyrosine kinase inhibition is the only
known medical treatment option for advanced GIST.
Due to the excellent bioavailability properties of
quizartinib, higher plasma concentrations are achieved
compared to other inhibitors with a similar sensitivity
profile. This may be advantageous in particular for the
treatment of solid tumor lesions.We treated an imatinib-sensitive GIST cell line
(GIST822) harboring a KIT exon 13 mutation (K642E)
and a second cell line, GIST48, harboring an imatinib-
sensitive V560D mutation plus a secondary imatinib-
insensitive activation loop mutation (D820A) with vary-
ing concentrations of quizartinib. Due to a much slower
in vitro cell doubling time of the GIST cell lines com-
pared to leukemic cell lines, GIST cells were treated for
7 days. Figure 5 demonstrates a potent proapoptotic ef-
fect of quizartinib targeting the KIT K642E mutation in
the GIST822 cell line, whereas the imatinib-insensitive
cell line GIST48 did not display any significant signs of
induction of apoptosis following quizartinib treatment.
Calculated IC50s are provided in Table 2.
Discussion
Tyrosine kinase inhibitors are rapidly entering into the
clinic. These agents are subject of intensive clinical in-
vestigation for the treatment of acute leukemia. For ex-
ample the following inhibitors are under investigation
for mutant ABL1, FLT3 or KIT-associated subtypes
(clinicaltrials.gov): sorafenib (e.g. AML: NCT00217646,
NCT00373373), sunitinib (e.g. AML: NCT00783653),
dasatinib (e.g. CBF-AML: NCT00850382; SM: NCT00979160;
Ph + ALL: NCT00103701, NCT00940524), imatinib (e.g.
AML: NCT00707408, NCT00744081; activated RTKs/
various tumors: NCT00171912), lestaurtinib (e.g. AML:
NCT00030186, NCT00079482), tandutinib (e.g. AML:
NCT00064584, NCT00274248), masitinib (e.g. SM:
NCT00814073) and nilotinib (e.g. AML: NCT01222143;
SM/HES: NCT00109707).
Quizartinib (formerly AC220), a N-(5-tert-butyl-
isoxazol-3-yl)-N’-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo
[2,1-b] [1,3] benzothiazol 2-yl]phenyl}urea dihydrochlo-
ride, is a novel class III tyrosine kinase inhibitor with
promising in vitro as well as in vivo activity against FLT3
wildtype and mutant isoforms [24]. Compared to
other tyrosine kinase inhibitors in evaluation for the
treatment of acute leukemia subtypes, quizartinib
provides superior bioavailability with longer and
higher plasma concentrations achieved in vivo [25]
thereby targeting and suppressing the activated ki-
nases more effectively.
Early data from a phase II trial of quizartinib in refrac-
tory or relapsed FLT3 ITD + patients revealed an accept-
able safety profile. Interim analysis of 62 patients (29
female, 33 male) was previously presented (Cortes, EHA
annual meeting 2011, #1019): Common drug-related ad-
verse events for evaluable patients were nausea, QTc
prolongation, vomiting, fatigue, dysgeusia, anorexia, fe-
brile neutropenia, diarrhea, and dyspepsia. Drug-related
severe adverse events in >15% of patients were febrile
neutropenia and asymptomatic Grade 3 QTc prolonga-
tion. 85% of patients were evaluable for efficacy: The
Figure 5 Quizartinib selectively induces apoptosis in gastrointestinal stromal tumor (GIST) cells. The imatinib-sensitive cell line GIST822,
harboring a KIT K642E mutation (A) and the imatinib-insensitive cell line GIST48, harboring a KIT V560D plus an additional D820A mutation, were
treated with quizartinib for 7 days and assayed for induction of apoptosis. Quadrant density dot plots are provided showing the apoptotic cell
fraction as indicated by annexin V positivity (LR quadrant: early apoptosis) and/or positive propidium iodide stain (UR: late apoptosis, UL: dead
cells) of quizartinib-treated versus treatment-naive cells. Estimated IC50s by non-linear dose regression analysis are provided with Table 2.
Kampa-Schittenhelm et al. Molecular Cancer 2013, 12:19 Page 11 of 15
http://www.molecular-cancer.com/content/12/1/19composite CR (CRc = CR + CRp + CRi) rate was 43% (1
CRp, 22 CRi) and PR rate was 28%. Of note, of the pa-
tients refractory to any prior therapy, 56% had CRc and
22% had PR in response to quizartinib treatment. 26% of
patients were bridged to allogenic transplantation
concepts.
We now report that quizartinib not only targets FLT3
wildtype and ITD mutant kinases [24] – but also po-
tently inhibits cellular proliferation and induces apop-
tosis of cells expressing a broad range of other clinically
relevant class III (mutant) RTK isoforms associated with
various diseases, including pediatric and adult leukemia
(FLT3 and KIT), GIST, seminoma and melanoma (KIT),
as well as myeloproliferative neoplasms associated with
eosinophilia (PDGFRA). Quizartinib-responsive muta-
tions were thereby detected in the juxtamembrane
(ITDs), but also the tyrosine kinase domains (TKD I -
K663Q, TKD II - D835Y) of FLT3, as well as in the KIT
JM- (V560G) and TK-domains (D816Y). However, as
with all tyrosine kinase inhibitors, quizartinib has a dis-
tinct potency profile against different autoactivating mu-
tant RTK isoforms - and some mutations in the TKD of
FLT3 (D835V, B1-sheet ITDs) and KIT (D816V) proved
to be resistant towards quizartinib. Resistancy of FLT3
ITD mutations located in the beta-1 sheet of the first
TKD has previously been shown for other TKI [32-34]
as well. In contrast to the BCR-ABL1 fusion transcript
demonstrating resistance towards quizartinib, the
FIP1L1-PDGFRA fusion mutation revealed extraordinary
sensitivity. In CBF AML, which is frequently dependent
upon KIT-mediated (gain-of-function) signal transduc-
tion, quizartinib demonstrated varying antiproliferativeand cytotoxic efficacy in in vitro and ex vivo leukemia
cells – in some cases within the low nanomolar range of
FLT3 ITD (JM) positive samples. However, the most
prevalent KIT mutation in CBF AML, substituting valine
for aspartic acid at codon 816 (KIT D816V), was dem-
onstrated to be basically insensitive towards quizartinib
in in vitro and ex vivo leukemia cell lines, primary mye-
loblasts, and in an isogenic Ba/F3 cell model – while
substitution of a tyrosine residue (D816Y) retained some
sensitivity to quizartinib. Therefore tyrosine kinase geno-
typing may become a prerequisite for clinical use of this
agent.
Moreover, based on our data, we speculate that
quizartinib may be a promising agent in solid tumors as-
sociated with KIT mutations, such as GIST or melanoma:
In addition to a favorable activity against KIT mutant
kinases expressed in GIST (and other mutant-KIT
neoplasms), the excellent pharmacokinetics with unprece-
dented achievable plasma concentrations may be advanta-
geous to target bulky solid tumor lesions that have
impaired drug uptake. Thus, our data opens new avenues
for clinical investigation and further testing of the efficacy
of quizartinib in these settings is warranted.
It has to be noted, that IC50s in our studies were
coherent in between all cell models used – but higher
compared to a previous report [24]. The phenomenon
was seen throughout the assays and is therefore most
likely due to methodology reasons as we have illustrated
with several experimental data:
While individual cell-context specific additional effects
(such as additional mutations) can not be fully excluded
to have obscured sensitivity profiles in some cell models,
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most of the discrepancies observed: In contrast to previ-
ous studies using serum-depleted culture conditions
(0.5% FBS), we used serum-repleted medium in all
assays (10% FBS for cell lines, 20% for native blasts).
Even more, data from Zarrinkar and colleagues were
based on treating refractory/relapsed AML samples
[24] – in contrast, samples tested in our assays were
isolated from patients with newly diagnosed disease.
However, it is believed that refractory/relapsed patient
samples have higher sensitivities towards TK-inhibition
due to a higher addiction to the respective oncogenic
(mutant) tyrosine kinase [37].
To underline our theories, we have provided substan-
tial experimental data using serum-deprived versus
serum-rich culture conditions in cell lines and native
blasts derived from newly diagnosed as well as relapsed
patients to treat with quizartinib in a dose dependent
manner. High correlation of serum-levels and achievable
IC50s was confirmed in all cell models. In addition,
treating newly diagnosed versus relapsed FLT3 ITD-
positive leukemia native patient samples, a higher sensi-
tivity profile for relapsed AML was verified. Thus, the
data will need to be interpreted in this context.
Conclusion
To summarize, our findings suggest that quizartinib is a
promising agent for treatment of several hematologic and
solid human neoplasms. However, due to the quizartinib-
specific mutation restricted spectrum of activity, tyrosine
kinase mutation screening may be required to identify
patients most likely to respond to quizartinib therapy.
Methods
Cell lines
The CML blast crisis cell line K562 was a generous gift
of Dr. Lopez, Oregon Health and Science University,
Portland, OR. The FLT3 ITD positive AML cell line
MOLM14 (heterozygous for an ITD of DFREYE at
amino acid position 593-598 [2]) was acquired through
the Fujisaki Cell Center (Okayama, Japan). The acute
myeloid leukemia cell line HL60, the KIT N822K posi-
tive CBF AML cell line Kasumi1 [41] and the FLT3 ITD
positive AML cell line MV4-11were obtained from the
German Collection of Microorganisms and Cell Cultures
(DSMZ). MV4-11 cells are hemizygous for an ITD of
amino acids VDFREYEYDH at position 592-601 [42].
The interleukin 3 (IL-3)–dependent murine pro-B cell
line Ba/F3, the FIP1L1-PDGFRA positive cell line EOL-1
[43], from a patient with eosinophilic leukemia following
hypereosinophilic syndrome [44], and the p815 mast cell
line was obtained from the American Type Culture
Collection (ATCC, Manassas, VA). The murine KIT
D814Y mutant isoform expressed by the p815 cell line[45] is homologous to the human KIT D816Y mutation.
The human hematopoietic growth factor–dependent
M-07e cell line was kindly provided by Dr. Hal Broxmeyer
(Department of Microbiology and Immunology, Walther
Oncology Center, Indiana University School of Medicine,
Indianapolis, IN). The human HMC-1.1 mast cell line, ex-
pressing a KIT juxtamembrane domain mutant isoform
(V560G), was provided by Dr. Butterfield (Division of Al-
lergic Diseases, Department of Internal Medicine, Mayo
Clinic, Rochester, MN). A spontaneously occurring
subclone of the HMC-1.1 cell line, HMC-1.2, which has
an additional mutation in the activation loop (D816V)
[46], was kindly provided by Dr. Akin (Laboratory of Al-
lergic Diseases, National Institute of Allergy and Infectious
Diseases, NIH, Bethesda, MD). All cell lines were cultured
in RPMI media containing 10% FBS.
M-07e cells were cultured using recombinant human
granulocyte-macrophage colony stimulating factor (GM-
CSF, R&D, Minneapolis, MN) as a growth supplement
as previously described [47]. Negativity for mycoplasma
contamination was confirmed using the pluripotent PCR
Mycoplasma test Kit (AppliChem, Darmstadt, Germany).
Cell lines harboring a mutant KIT, FLT3 or BCR-ABL1
were sequence confirmed.
The gastrointestinal stromal tumor cell lines GIST822,
harboring a KIT exon 13 mutation (K642E), and
GIST48, harboring an imatinib-sensitive V560D muta-
tion plus a secondary imatinib-insensitive activation loop
mutation (D820A) were generously provided by Dr.
Kopp (University of Tübingen) [48,49].
Site-directed mutagenesis and generation of a Ba/F3 cell
line expressing KIT or FLT3 isoforms
Site-directed mutagenesis and generation of Ba/F3 cell
lines stably expressing mutant KIT D816V, D816Y,
D816F, FLT3 ITD, D835Y, D835Y, K663Q and FLT3
wildtype were performed as previously described
[50-52].
KIT Wildtype cDNA cloned into a pJP1563 plasmid
vector was obtained from the DNASU Plasmid Repository
at the Biodesign Institute of the Arizona State University
(ASU). Lipofection transfection into the parental Ba/F3
cell line was performed to stably express KIT Wildtype by
double selection for neomycin (pCMVneo plasmid),
blasticidin (pJP1563 plasmid) or gentamicin (G418; all
other plasmids) resistance and IL-3-independent growth.
The Ba/F3 KIT Wildtype cell line was cultured using re-
combinant human stem cell factor (SCF/KITLigand, R&D,
Minneapolis, MN) as a growth supplement.
Antibodies and reagents
The small-molecule compounds quizartinib was obtained
from Ambit Biosystems and dissolved in DMSO to create
10 mmol/L stock solutions and stored at −20°C.
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used at a 1:5,000 to 1:1,000 dilution. Antiphosphotyrosine
p-KIT antibodies (Tyr568/570 and Tyr703), p-FLT3
antibodies (Tyr 589/591) and a pan-antiphosphotyrosine
antibody (clone PY20) were administered at dilutions of
1:100 to 1:2,000 (all from Cell Signaling Technology).
Infrared dye-conjugated secondary goat anti-rabbit or
anti-mouse antibodies to use in a LI-CORW imaging
detection system were prepared according to standard
protocols (LI-COR Biosciences, Lincoln, NE).
Isolation of bone marrow and peripheral blood
mononuclear cells
Bone marrow aspirate and peripheral blood samples
from patients with AML were collected in 5000 U hep-
arin after informed consent and approval of the ethics
committee of the University of Tübingen or Ulm. Mono-
nuclear cells were isolated by Ficoll Hypaque density
gradient fractionation [35]. Additional acute myeloid
leukemia samples were generously provided by the
German-Austrian AML Study Group (AMLSG) leuke-
mia biobank (patient characteristics summarized in
Additional file 2: Table S1). Native ex vivo blasts were
cultured in DMEM media containing 20% FBS.
Immunoblotting
Cell pellets were lysed with 100 to 150 μL of protein
lysis buffer (50 mmol/L Tris, 150 mmol/L NaCl, 1%
NP40, 0.25% deoxycholate with added inhibitors aprotinin,
AEBSF, leupeptin, pepstatin, sodium orthovanadate, and
sodium pyruvate, respectively phosphatase inhibitor cock-
tails „2“ and „1“ or „3“ (Sigma, St. Louis, MO). Protein
from cell lysates (75 to 200 μg protein) was used for whole
cell protein analysis after denaturing by Western immuno-
blot assays using a BioRad Criterion system (protein separ-
ation by SDS-PAGE in 3-8% or 10% polyacrylamide gels
followed by electroblotting onto nitrocellulose mem-
branes). Nonspecific binding was blocked by incubating
the blots in nonfat dry milk or BSA. Primary antibodies
were incubated for one hour or over night, followed
by several washes of Tris-buffered saline (TBS) con-
taining 0.005% Tween 20. The appropriate secondary
antibody was applied for 30‘, followed by several washes.
Antibody-reactive proteins were detected using a LI-
COR OdysseyW fluorescence optical system (LI-COR
Biosciences, Lincoln, NE).
Apoptosis and cell viability assays
Induction of apoptosis upon quizartinib treatment was
assayed in dilution series (0 – 5000 nM) and transloca-
tion of phosphatidylserine from the inner to the outer
leaflet of the plasma membrane as an early indicator of
apoptosis was analyzed using an Annexin V-based assay
(Immunotech, Marseilles, France) and a FACScaliburWflow cytometer loaded with CellQuestW analysis software
(BD, Heidelberg, Germany) [27,47].
A proportion of ex vivo leukemia blasts were not avail-
able for induction of apoptosis assays using Annexin V/PI
staining due to a higher percentage of apoptotic cells in
the untreated negative control population. Nevertheless,
viability assays were assessed using FSC/SSC-flow cytome-
try experiments with a gate on the living cell population.
Reduction of viable cells in the presence of quizartinib
was measured 48 hours post quizartinib treatment.
Proliferation assays
Cells were added to 96-well plates at densities of 50 000
cells per well. Quizartinib was added in dilution series
(0 – 5000 nM) and proliferation was measured at 48 hours
using an 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-
tetrazolium-5-carboxanilide inner salt (XTT)–based assay
(Sigma, MO) [27,47].
Polymerase Chain Reaction (PCR) and Sequencing
Genomic DNA was isolated using a DNeasyW DNA
purification kit (Qiagen, Hilden, Germany). FLT3 muta-
tion status was assessed by routine standard PCR tech-
niques. KIT mutation status of exon 8, 9, 11, 13 and 17
was analyzed by PCR followed by bidirectional sequen-
cing. The primer sets are as follows: KIT exon 8, sense:
GCT GAG GTT TTC CAG CAC TC; KIT exon 8, anti-
sense: AAT TGC AGT CCT TCC CCT CT; KIT exon 9,
sense: AGCCAGGGCTTTTGTTTTCT; KIT exon 9,
antisense: CAGAGCCTAAACATCCCCTTA; KIT exon
11, sense: CCTTTGCTGATTGGTTTCGT; KIT exon
11, antisense: AAACAAAGGAAGCCACTGGA; KIT
exon 13, sense: GTTCCTGTATGGTACTGCATGCG;
KIT exon 13, antisense: CAGTTTATAATCTAGCATTG
CC; KIT exon 17, sense: GGTTTTCTTTTCTCCTCCA
ACC; KIT exon 17, antisense: GGATTTACATTATGA
AAGTCACAGG.
Data analysis
Inhibition of proliferation or the proportion of apop-
totic/viable cells was assessed in dilution bar diagrams.
Non-linear 4-parameter median-effect regression ana-
lysis was performed to compute IC50s using PrismW
(GraphPad Software, Inc., LaJolla, CA) or MasterPlexW
software (Hitachi Solutions, Tokyo, Japan).
Additional files
Additional file 1: Figure S1. Native FLT3 ITD positive patient blasts
were treated with quizartinib in a dose-dependent manner and cultured
in serum reduced (0.5%) versus serum repleted (20%) conditions. Cells
were incubated for 48 hours and induction of apoptosis was measured
using an annexin V-based assay. Densitiy plots for quizartinib at 10 nM
are shown - estimated IC50s are provided with Table 2.
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characteristics is available at the website of MOLECULAR CANCER
(see “Additional file 2: Table S1/Additional file 1: Figure S1”).
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